1
CARDIOVASCULAR
hamburger

MOMENTUM 3 SHORT-TERM COHORT

294 PATIENTS FOLLOWED FOR SIX MONTHS

Six-Month Primary Outcomes in the MOMENTUM 3 Short-Term Cohort

Mehra, M.R., Naka, Y., Uriel, N., Goldstein, D.J., Cleveland, J.C., Colombo, P.C., …, Salerno, C., for the MOMENTUM 3 Investigators. (2017). A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med, 376(5), 440-50. https://www.nejm.org/doi/10.1056/NEJMoa1610426.

In this primary six-month analysis of the MOMENTUM 3 trial, the HeartMate 3 LVAS demonstrates:

  • Improvement in outcomes driven by a reduction in the need for reoperation or replacement of the HeartMate 3 pump.
  • Patients treated with either the HeartMate 3 LVAS or the HeartMate II LVAS show similar functional quality of life improvement.
  • No suspected or confirmed pump thrombosis events.

Hemocompatibility Related Outcomes at Six Months in the MOMENTUM 3 Short-Term Cohort

Uriel, N., Colombo, P.C., Cleveland, J.C., Long, J.W., Salerno, C., Goldstein, D.J., … Mehra, M.R. (2017). Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. Circulation, 135(21), 2003-12. https://doi.org/10.1161/CIRCULATIONAHA.117.028303

In this secondary analysis of the MOMENTUM 3 trial, the HeartMate 3 LVAS demonstrated higher freedom from an aggregate of hemocompatibility-related adverse events at six months in comparison to HeartMate II LVAS.

Impact of Age, Sex, Therapeutic Intent, Race and Severity of Advanced Heart Failure on Six-Month Outcomes in the MOMENTUM 3 Short-Term Cohort

Goldstein, D.J., Mehra, M.R., Naka, Y., Salerno, C., Uriel, N., Dean, D., … Cleveland, J. for the MOMENTUM 3 Investigators. (2018). Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial, J Heart Lung Transplant, 37 (1), 7-14. https://doi.org/10.1016/j.healun.2017.11.001

This analysis of the MOMENTUM 3 trial demonstrates the following:

  • Younger age at implant and pump choice of HeartMate 3 LVAS versus HeartMate II LVAS were independently associated with a greater likelihood of primary endpoint success.
  • Sex, therapeutic intent, severity of illness and race, when adjusted for age, do not influence primary endpoint success.

Quality of Life and Functional Capacity Outcomes at Six Months in the MOMENTUM 3 Short-Term Cohort

Cowger, J.A., Naka, Y., Aaronson, K.D., Horstmanshof, D., Gulati, S., Rinde-Hoffman, D., … Jorde, U.P. on behalf of the MOMENTUM 3 Investigators. (2018). Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients. J Heart Lung Transplant, 37 (1), 15-24. https://doi.org/10.1016/j.healun.2017.10.019

The analysis of this study on health-related quality of life (HR-QOL) and functional capacity shows that:

  • HR-QOL and functional capacity improved significantly in MOMENTUM 3 patients, independent of device use.
  • Two-thirds of patients met the endpoint of “Living Well on an LVAD” at six months.
  • Occurrence of an early serious adverse event did not influence HR-QOL but functional capacity was adversely affected.

MAT-2006847 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.